Idenix Pharmaceuticals has begun patient enrollment in a Phase II trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir (Idenix’s once-daily pan-genotypic NS5A inhibitor), simeprevir (a once-daily NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB), and TMC647055 (a once-daily NS5B non-nucleoside polymerase inhibitor boosted with low-dose ritonavir developed by Janssen). The trial is a 12-week, randomized, open...